title: Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
abstract: Metaphase cytogenetic abnormalities (CAs), especially of chromosome 13 (CA 13), confer a grave prognosis in multiple myeloma even with tandem autotransplantations as applied in Total Therapy I, which enrolled 231 patients between 1989 and 1994. With a median follow-up of almost 9 years, the prognostic implications of all individual CAs, detected prior to treatment and at relapse, were investigated. Among all CAs and standard prognostic factors examined prior to therapy, only hypodiploidy and CA 13 (hypo-13 CA), alone or in combination, were associated with shortest event-free survival and overall survival (OS). The shortest postrelapse OS was observed with hypo-13 CA, which was newly detected in 18 of all 28 patients presenting with this abnormality at relapse. Superior prognosis was associated with the absence of any CA at both diagnosis and relapse (10-year OS, 40%). The lack of independent prognostic implications of other CAs points to a uniquely aggressive behavior of hypo-13 CA (present in 16% of patients at diagnosis). With the use of microarray data in 146 patients enrolled in Total Therapy II, overexpression of cell cycle genes distinguished CA from no CA, especially in cases of del(13) detected by interphase fluorescence in situ hybridization (FISH). FISH 13, resulting in a haploinsufficiency of RB1 and other genes mapping to chromosome 13, as well as activation of IGF1R, appears to have an amplifying effect on cell cycle gene expression, thus providing a molecular explanation for the dire outcome of patients with CA 13 compared with those with other CAs.
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
authors.forename: John
authors.initials: J
authors.lastname: Shaughnessy
authors.forename: Joth
authors.initials: J
authors.lastname: Jacobson
authors.forename: Jeff
authors.initials: J
authors.lastname: Sawyer
authors.forename: Jason
authors.initials: J
authors.lastname: McCoy
authors.forename: Athanasios
authors.initials: A
authors.lastname: Fassas
authors.forename: Fenghuang
authors.initials: F
authors.lastname: Zhan
authors.forename: Klaus
authors.initials: K
authors.lastname: Bumm
authors.forename: Joshua
authors.initials: J
authors.lastname: Epstein
authors.forename: Elias
authors.initials: E
authors.lastname: Anaissie
authors.forename: Sundar
authors.initials: S
authors.lastname: Jagannath
authors.forename: David
authors.initials: D
authors.lastname: Vesole
authors.forename: David
authors.initials: D
authors.lastname: Siegel
authors.forename: Raman
authors.initials: R
authors.lastname: Desikan
authors.forename: Nikhil
authors.initials: N
authors.lastname: Munshi
authors.forename: Ashraf
authors.initials: A
authors.lastname: Badros
authors.forename: Erming
authors.initials: E
authors.lastname: Tian
authors.forename: Maurizio
authors.initials: M
authors.lastname: Zangari
authors.forename: Guido
authors.initials: G
authors.lastname: Tricot
authors.forename: John
authors.initials: J
authors.lastname: Crowley
authors.forename: Bart
authors.initials: B
authors.lastname: Barlogie
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D002882:Chromosomes, Human, Pair 13; D004171:Diploidy; D005500:Follow-Up Studies; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008677:Metaphase / Q000235:genetics; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D013997:Time Factors